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Abstract
Metformin is now being recognized as the standard therapy in T2D patients who are overweight. Metformin has many drug-disease 
interactions that can increase the risk of metformin-associated lactic acidosis. Therefore this study was conducted to evaluate any 
possible pharmacodynamic interactions between metformin and drugs used to treat chronic diseases e.g. Hypertension. The rats 
were fasted overnight before inducing diabetes with streptozotocin. The rats were given an intraperitoneal injection of streptozotocin 
(50 mg kg−1) freshly prepared in 0.1M sodium citrate buffer. The diabetic state was confirmed 72 h after streptozotocin injection. 
Diabetic rats were grouped into seven groups each group of five rats and distributed among the normal control group diabetic 
control group and the treatment groups. The treatment continued for 10 days. Blood samples were taken before treatment and 
after 10 days and analyzed for serum glucose, cholesterol, HDL, LDL, and triglycerides. In the diabetic control group which was 
given STZ alone the blood glucose level decreased significantly (p < 0.05) after 10 days but still above the hyperglycemic level 
(200mg/dl). The same was observed in the group treated with metformin. The group treated with nifedipine and aspirin showed 
significant reduction (p < 0.01) in the glucose level below the hyperglycemic level (200mg/dl). While the groups treated with 
(Metformin + Nifedipine) and (Metformin +Aspirin) showed highly significant reduction (P<0.001) in blood glucose level. These 
results conclude that the combination of (metformin +Nifedipine) and the combination of (Metformin + Aspirin) have highly 
significant hypoglycemic effect. It also showed that Nifedipine has promising role in reducing blood glucose level, lipid profile 
especially LDL-cholesterol, and body weight. 
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1. Introduction
Diabetes mellitus (DM) is a chronic metabolic disorder 
characterized by a hyperglycemia caused by insulin defi-
ciency, often combined with insulin resistance. In diabetes, 
the homeostasis of carbohydrate and lipid metabolism is 
improperly regulated by the pancreatic hormone, insulin; 
resulting in an increased blood glucose level1. 
Hyperglycemia occurs because of uncontrolled 
hepatic glucose output and reduced uptake of glucose by 
skeletal muscle with reduced glycogen synthesis. Diabetes 
mellitus is classified on the basis of the pathogenic process 
that leads to the hyperglycemia. The broad categories of 
DM are designated type 1 and type 22. 
Metformin lowers blood glucose concentration and 
improves insulin sensitivity by reducing hepatic gluco-
neogenesis and enhancing insulin-simulated peripheral 
glucose uptake. It also inhibits adipose tissue lipolysis, 
thereby reducing circulating levels of free fatty acids 
(FFA)3. 
 Metformin, an oral anti-diabetic drug, is being con-
sidered increasingly for treatment and prevention of 
cancer, obesity as well as for the extension of healthy life 
span4. 
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Metformin is not metabolised at all but is completely 
excreted in urine. Metformin may therefore accumu-
late and cause lactic acidosis if other medications have 
induced renal failure5. 
When patients are diagnosed with diabetes, a large 
number of medications become appropriate therapy. 
These include medications for dyslipidemia, hyperten-
sion, antiplatelet therapy, and glycemic control which 
may lead to drug interactions with antidiabetic drugs6. 
Metformin has many drug-disease interactions that can 
increase the risk of metformin-associated lactic acidosis 
(MALA)6. 
Drug interactions are often categorized as phar-
macodynamic or pharmacokinetic in nature6. A 
pharmacodynamic drug interaction is related to the drug’s 
effect on the body. Pharmacodynamic drug interactions 
can be either beneficial or detrimental to patients6. 
Any drug that has the potential to raise blood glucose 
may produce apparent inefficacy of an oral hypoglycae-
mic drug. Stopping a drug which causes hyperglycaemia 
may produce a significant fall in blood glucose. This may 
require a parallel reduction in the dose of a hypoglycemic 
drug5.
Some drugs can lower blood glucose, but the mecha-
nisms of action are not well understood. Taking one of 
these drugs with a hypoglycemic drug might cause clini-
cally significant hypoglycaemia. The patient may need a 
lower dose or even have to cease the oral hypoglycemic 
drug. Conversely stopping a drug with the potential to 
lower blood glucose might produce relative inefficacy of 
a hypoglycemic drug and create a need for an increased 
dose5.
2.  Justification of the Study
It has been reported that diabetic patients may take other 
drugs to treat concomitant diseases. Diabetic patients 
may be administered antihypertensive drugs, NSAIDs, 
anti-ulcer drugs which may interact with metformin. 
Therefore this study was conducted to evaluate any pos-
sible pharmacodynamic interactions between metformin 
and drugs used to treat chronic diseases e.g. Hypertension
3.  Materials and Methods
3.1 Chemicals
Streptozocin (Manufactured by Sigma- Aldrich, USA) 
was purchased from a local distributor in KSA, Sodium 
Citrate (Manufactured by Lobel Chemie, laboratory 
reagents & fine chemical, India) was availed from the lab-
oratory stock at Northern Border University
Metformin (Glucophage 500 mg, Merck santé, 
France), Aspirin100 mg (Bayer, Germany) and Nifedipine 
(Adalat 20 mg, Bayer, Germany) were purchased from the 
local market.
3.2 Method of Analysis
Samples were analyzed for serum glucose, cholesterol, 
HDL, LDL, and triglycerides using the kits of Human 
Diagnostic Worldwide. 
3.3 Experimental Animals
Wistar albino rats of either sex were used (Table 2) were 
obtained from the animal house at the faculty of phar-
macy, Northern Border University. The animals were 
housed in a standard controlled animal care facility. The 
animals were maintained under standard nutritional and 
environmental conditions throughout the experiment 
and water was given ad libitum. 
3.4 Induction of Diabetes
Rats were fasted overnight before inducing diabetes with 
streptozotocin. Streptozotocin is used to induce both type 
I and Type II diabetes based on the dose i.e. it is concen-
tration dependent, for the induction of type I, 60 mg/kg is 
given intraperitoneally or intravenously , and for type II 
induction 40-50mg/kg is the usual dose used1,7,8 . In this 
study the rats were given an intraperitoneal injection of 
streptozotocin (50 mg kg−1) freshly prepared in 0.1M 
sodium citrate buffer. The diabetic state was confirmed 72 
h after streptozotocin injection. Threshold value of fasting 
blood glucose was taken as >200 mg dL−18. Diabetic rats 
were weighed and matched for body weight and divided 
into following groups consisting five animals each: 
• Group 1: Normal control 
• Group 2: Diabetic Control 
• Group 3: Diabetic rats administered Metformin 100 
mg/kg (10 days, p.o.).
• Group 4: Diabetic rats administered Aspirin 100 mg/
kg (10 days, p.o.).
• Group 5: Diabetic rats administered Nifedipine 20 
mg/kg (10 days, p.o.).
• Group 6: Diabetic rats administered Metformin 100 mg/
kg (10 days, p.o.) + Aspirin 100 mg/kg (10 days, p.o.).
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3.7 Body Weight Determination
Weight of rats was recorded before and after the study 
period of 10 days. 
4.  Results
As shown in Table 1, a paired- samples t-test was con-
ducted to compare the glucose level in rats with STZ 
induced hyperglycemia before treatment (time zero) 
and after 10 days. There was a highly significant differ-
ence (p < 0.001) in the groups treated with (Metformin + 
Nifedipine) and (Metformin + Aspirin).
Figure 1 compare the glucose level in rats with STZ 
induced hyperglycemia before treatment (time zero) 
• Group 7: Diabetic rats administered Metformin 100 
mg/kg (10 days, p.o.) + Nifedippine 20 mg/kg (10 
days, p.o.).
3.5 Blood Glucose Estimation
Blood sample were collected from the retro orbital plexus 
of the rats and glucose was estimated before (day 0) and 
after treatment (day 10). 
3.6 Blood Lipids Estimation
Blood samples were assessed for total cholesterol, HDL, 
LDL and triglycerides before (day 0) and after treatment 
(day 10).
Figure 1. Effect of metformin, nifedipine and Aspirin on fasting glucose level.
Table 1. Effect of drugs (Metformin, Aspirin, Nifedipine) on fasting 
blood glucose levels in STZ induced diabetes
Group 
No.
Treatment
(n = 5)
Blood Glucose (mg/dl) (Mean ± SEM)
Day 0 Day 10
1 Diabetic control (STZ) 394.60 ± 44.35 224.51 ± 61.90 *↓
2 Metformin 525.53 ± 15.17 312.09 ± 43.81 *↓
3 Nifedipine 269.60 ± 34.76 139.16 ± 19.10 *↓
4 Metformin + Nifedipine 555.80 ± 6.89 142.53 ± 17.60 ***↓
5 Aspirin 229.30 ± 40.08 150.00 ± 48.99 *↓
6 Metformin + Aspirin 574.70 ± 57.47 197.28 ± 53.41 ***↓
*↓ Significant decrease (p < 0.05) ***↓ Highly significant decrease (p < 0.001) (paired samples 
T-test) compared Day 10 to Day 0.
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and after 10 days of treatment in different treatment 
groups.
Table 2 shows a paired- samples t-test was conducted 
to compare the body weight in rats with STZ induced 
hyperglycemia before treatment (time zero) and after 10 
days. There was a highly significant reduction (p < 0.001) 
in the group treated with Nifedipine. 
Figure 2 show a comparison of body weight in rats 
with STZ induced hyperglycemia before treatment (time 
zero) and after 10 days of treatment in different treatment 
groups.
As shown in Table 3 a paired- samples t-test was con-
ducted to compare the lipids level in rats with STZ induced 
hyperglycemia before treatment (time zero) and after 10 
days. There was a highly significant reduction (p < 0.001) 
in LDL – cholesterol concentration in the group treated 
with Nifedipine.
Figure 3 compare the lipid profile in rats with STZ 
induced hyperglycemia before treatment (time zero) and 
after 10 days of treatment in different treatment groups.
5. Discussion
The prevalence of diabetes is high among the Saudi popu-
lation and represents a major clinical and public health 
problem9,10 and many patients taking antidiabetic drugs 
Table 2. Effect of Metformin, Aspirin, and Nifedipine on body 
weight in STZ induced diabetes
Group 
No.
Treatment
(n = 5)
Body weight (g) (Mean ± SEM)
Day 0 Day 10
1 Diabetic control (STZ) 176.00 ± 11.99 191.66 ± 10.75 *↑
2 Metformin 177.00 ± 5.35 178.50 ± 6.84
3 Nifedipine 228.40 ± 9.23 192.00 ± 8.79 ***↓
4 Metformin + Nifedipine 181.60 ± 8.41 184.50 ± 9.08
5 Aspirin 195.40 ± 13.11 201.00 ± 21.46
6 Metformin + Aspirin 167.20 ± 5.64 167.50 ± 4.61
*↓ Significant decrease (p < 0.05 ) ***↓ Highly significant decrease (p < 0.001) (paired 
samples T-test) compared Day 10 to Day 0.
Figure 2. Effect of metformin, aspirin, and nifedipine on body weight.
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and antihypertensive drugs concomitantly which may 
lead to various drug-drug interactions. Therefore the 
main objective of this work was to study the pharma-
codynamic interactions between metformin, nifedipine, 
and aspirin and their effects on blood glucose level, lipid 
profile and body weight.
In this study streptozocin (STZ) when adminis-
tered intraperitoneally (IP) to rats the blood glucose 
level increased above 200 mg/dl within 48-72 hours 
which considered hyperglycemic. In the diabetic 
control group which was given STZ alone the blood 
glucose level decreased significantly (p < 0.05) after 10 
days but still above the hyperglycemic level (200mg/
dl). The same was observed in the group treated with 
metformin. On the other hand the group treated with 
nifedipine and aspirin showed significant reduction (p 
Table 3. Effect of Metformin, Aspirin, and Nifidipine on blood lipid levels in STZ induced diabetes
Group 
No.
Treatment
(n = 5)
Total Cholesterol (mg/
dl) (Mean ± SEM)
LDL (mg/dl)
(Mean ± SEM)
HDL (mg/dl)
(Mean ± SEM)
TG (mg/dl)
(Mean ± SEM)
Day 0 Day 10 Day 0 Day 10 Day 0 Day 10 Day 0 Day 10
1 Diabetic control 
(STZ)
62.63± 
7.08 
74.98 ± 
7.19 *↑ 
44.31 ± 
6.87
12.72 ± 
4.50 *↓
178.98± 
62.56 
38.94 ± 
8.88
103.84 ± 
24.06
83.59 ± 
14.59
2 Metformin 68.69 ± 
6.70
62.55 ± 
13.30
52.64 ± 
4.13
16.76 ± 
4.35*↓ 
197.40 ± 
58.42
31.52± 
6.07 
122.85 ± 
19.52
155.99 ± 
64.54
3 Nifedipine 57.63 ± 
11.74
46.84 ± 
5.32
20.05 ± 
2.41
11.73 ± 
2.22 ***↓
27.85 ± 
5.23
31.13 ± 
4.17
194.02 ± 
71.29
66.90 ± 
36.48
4 Metformin + 
Nifedipine
61.01 ± 
9.87
48.20 ± 
5.65
59.66 ± 
13.96
6.80 ± 
1.48 *↓
137.62 ± 
33.24 
14.60 ± 
2.98 *↓
82.65 ± 
8.34
35.93 ± 
4.65 *↓ 
5 Aspirin 72.07 ± 
8.25
87.11 ± 
23.17
11.47 ± 
2.58
7.23 ± 
3.55
16.36 ± 
5.73
29.10 ± 
7.76
74.94 ± 
12.59
32.90 ± 
11.03 *↓
6 Metformin + Aspirin 63.03 ± 
3.81
73.47 ± 
7.95
144.32 ± 
88.68
17.19 ± 
1.85
223.34 ± 
80.63
26.32 ± 
6.25
88.74 ± 
28.66
144.19 ± 
52.95
*↓ Significant decrease (p < 0.05 ) ***↓ Highly significant decrease (p < 0.001 ) (paired samples T-test) compared Day 10 to Day 0.
Figure 3. Effect of metformin, nifedipine and aspirin on blood lipid levels in STZ induced diabetes.
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< 0.01) in the glucose level below the hyperglycemic 
level (200mg/dl). 
Interestingly, the groups treated with (Metformin + 
Nifedipine) and (Metformin +Aspirin) showed highly 
significant reduction (P<0.001) in blood glucose level. 
Taking one of these drugs with a hypoglycemic drug 
might cause clinically significant hypoglycaemia. The 
patient may need a lower dose or even have to cease the 
oral hypoglycemic drug. Conversely stopping a drug with 
the potential to lower blood glucose might produce rela-
tive inefficacy of a hypoglycemic drug and create a need 
for an increased dose5. Therefore patients taking metfor-
min with nifedipine or aspirin need close monitoring for 
blood glucose level.
 Suresha et al. reported that Nifedipine worsens gly-
cemic control in normal rats after glucose challenge 
through inhibition of basal insulin secretion11. Jobran Al 
Qahtani et al. also reported that Nifedipine has induced 
hyperglycemia in an infant12. These results does not go on 
line with our finding regarding the effect of Nifedipine, 
in which Nifedipine has reduced blood glucose level in 
STZ induced hyperglycemia in rats. However, our finding 
agreed with the finding of Kaymaz et al. who concluded 
that calcium channel blockers (Nifedipine) have ben-
eficial effects on body weight, glycated hemoglobin and 
blood glucose level13. Choi and Lee reported that the com-
bination of nifedipine and metformin caused reduction in 
blood glucose level which may be due to the fact that both 
metformin and nifedipine are commonly metabolized via 
hepatic CYP2C and 3A subfamilies in rats. Therefore; 
simultaneous administration of both drugs may lead to 
an increase of the bioavailability of both drugs due to 
competitive inhibition for the metabolism of nifedipine 
and metformin by each other via intestinal CYP3A1/2 in 
addition to competitive inhibition for hepatic metabolism 
of each drug14. 
In a study performed to investigate the beneficial 
effects of nifedipine on abnormalities of platelets and lipid 
metabolism in patients with type II diabetes mellitus, it 
was found nifedipine produced significant reduction of 
lipid profiles except for HDL which showed significant 
increase15. This result agrees with our findings which 
demonstrated that nifedipine produced highly significant 
reduction in LDL-cholesterol blood level in rats.
Many studies documented that Aspirin can signifi-
cantly decrease blood glucose level16 which is in agree 
with our findings in this study. It is claimed that Aspirin 
can cause decrease in basal rates of hepatic glucose pro-
duction, enhances tissue insulin sensitivity, decreases 
insulin clearance, and decreases oxidative stress in dia-
betic patients17,18. 
In this study Nifedipine produced highly significant 
reduction (P> 0.001) in body weight in the rats with STZ 
induced hyperglycemia. In addition Nifedipine showed 
highly significant (P<0.001) decrease in LDL-cholesterol 
concentration compared to day zero for the same group; 
While Aspirin produced significant (p< 0.05) reduction 
in triglycerides (TG) concentration. 
6.  Conclusion
From this study we conclude that the combination 
of (metformin + Nifedipine) and the combination of 
(Metformin + Aspirin) have highly significant antidia-
betic effect which might be helpful for diabetic patients 
with concomitant hypertension. Our study showed that 
Nifedipine has promising role in reducing blood glucose 
level, lipid profile especially LDL-cholesterol, and body 
weight. 
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